Professor Charles E. Geyer: neoadjuvant therapy is becoming standard of care for HER2+ breast cancer.
Editorial Office, Chinese Clinical Oncology, AME Publishing Company, Guangzhou 510220, China. editor@thecco.net.
Lucille L
LL
Ye
D001943:Breast Neoplasms / Q000201:enzymology* / Q000628:therapy*; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human